Equities analysts forecast that Dyadic International, Inc (NASDAQ:DYAI) will post $520,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Dyadic International’s earnings, with estimates ranging from $430,000.00 to $600,000.00. Dyadic International posted sales of $460,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 13%. The business is scheduled to issue its next earnings results on Wednesday, November 11th.
According to Zacks, analysts expect that Dyadic International will report full-year sales of $1.83 million for the current year, with estimates ranging from $1.72 million to $2.00 million. For the next year, analysts forecast that the company will report sales of $2.20 million, with estimates ranging from $1.75 million to $3.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Dyadic International.
Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Dyadic International had a negative net margin of 480.72% and a negative return on equity of 23.81%. The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.46 million.
A number of equities analysts have recently weighed in on the stock. TheStreet cut shares of Dyadic International from a “c” rating to a “d+” rating in a research note on Friday, September 4th. Noble Financial reiterated a “buy” rating and issued a $11.00 price objective on shares of Dyadic International in a research report on Friday, August 14th.
Shares of DYAI opened at $7.71 on Wednesday. The stock has a market capitalization of $211.89 million, a P/E ratio of -24.87 and a beta of 0.39. The company’s fifty day moving average is $8.18 and its two-hundred day moving average is $6.91. Dyadic International has a 1 year low of $2.51 and a 1 year high of $10.98.
A number of large investors have recently added to or reduced their stakes in DYAI. Strs Ohio purchased a new position in Dyadic International in the 2nd quarter valued at about $42,000. UBS Group AG lifted its holdings in shares of Dyadic International by 104.8% during the 2nd quarter. UBS Group AG now owns 6,127 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 3,136 shares during the period. SG Americas Securities LLC purchased a new position in shares of Dyadic International during the 2nd quarter worth about $91,000. American International Group Inc. purchased a new position in shares of Dyadic International during the 2nd quarter worth about $102,000. Finally, Jane Street Group LLC purchased a new position in shares of Dyadic International during the 1st quarter worth about $115,000. Institutional investors own 20.11% of the company’s stock.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
Featured Story: What is the Ex-Dividend Date in Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.